Tags
- 2027
- 2035
- 3Q
- A
- Absence
- Activate
- Alpha
- A major
- An
- Analyst
- Anthony Moore
- Antigen
- Approval
- Arms
- Based on
- Baseline
- Benefit
- Bio
- Bristol-Myers Squibb
- Broad
- Cancer
- Cancer Cell
- Cancer immunotherapy
- Cancer vaccine
- Cause
- CD8
- Cell
- Cells
- Challenge
- Challenges
- Checkpoint
- Checkpoint inhibitors
- Chemotherapy
- Chose
- Circulating tumor DNA
- Clinical
- Clinical effect
- Clinical endpoint
- Colorectal cancer
- Complement
- Concern
- Consensus
- Control Group
- Correlation
- CRC
- Cytotoxicity
- Cytotoxic T cell
- Data
- Data release
- Decline
- Defined
- Designation
- Diagnosis
- Disease
- Disease progression
- Distinct
- DNA
- Effect
- Endpoint
- Enlargement
- Evaluation
- Exclusive
- Expect
- Expression
- Face
- Faces
- Failure
- Fast Track
- FDA
- Feces
- Following
- Food and Drug Administration
- Fraction
- Gambia Radio & Television Service
- Generate
- Granite
- Gritstone
- Hazard
- Heterogeneity
- Immune
- Immune response
- Immunogenicity
- Immunotherapy
- Induce
- Infiltration
- Inhibitor
- In-phase and quadrature components
- Large intestine
- Liver
- Long run and short run
- Maintenance
- Maintenance therapy
- Market
- Mature
- Measurement
- Merck
- Metastases
- Metástasis
- Missé
- Misunderstanding
- Molecule
- NASDAQ
- Need
- Neoantigens
- Neoplasm
- Newly diagnosed
- Next Generation
- Nivolumab
- Normal
- Novel
- Obligatio consensu
- Only
- Patient
- Pembrolizumab
- Peptide
- Peptides
- Perception
- Personalization
- PFS
- Phase
- PHASE 2
- Platform
- Population
- Portion
- POS
- Potent
- Primary
- Probability
- Probability of success
- Progression
- Progression-free survival
- Projected
- Pronunciation
- Repertoire
- Result
- Revenue
- Risk
- Salient
- Secondary
- Short
- Sometimes
- Statistical significance
- Statistics
- Subgroup
- Success
- Survival
- Survival analysis
- Targeted
- T cell
- Temporary
- Term
- The Control Group
- Therapy
- The Tumor
- Trend
- Trends
- Trial
- Trials
- Tumor
- Tumor antigen
- Tumor antigens
- Tumor dna
- Vaccine
- Visible
- Who